

**Oncimmune Holdings plc**

("Oncimmune" or the "Company")

**Posting of Notice of General Meeting**

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, today announces that it has sent a notice of a General Meeting ("GM") to shareholders, to be held at 11:00 a.m. GMT on 10 March 2025 at 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT. The principal purpose of the GM will be to approve the Company's Annual Report and Accounts for the financial year ended 31 August 2024 ("Annual Report") which was published today. The Annual Report and the notice of GM can be viewed on the "Investors" section of the Company's website at [www.oncimmune.com](http://www.oncimmune.com).

**For further information:**  
[contact@oncimmune.com](mailto:contact@oncimmune.com)

**Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)**

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)  
Nigel Birks (Life Science Specialist Sales)  
Ondraya Swanson (Corporate Broking)  
+44 (0) 20 7220 0500

**Zeus (Joint Broker)**  
Dominic King  
+44 (0)20 3829 5000

**About Oncimmune**

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit [www.oncimmune.com](http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOGVFLFELLBBBV